Literature DB >> 31081121

Improving tumour budding evaluation in colon cancer by extending the assessment area in colectomy specimens.

Carolina Martinez-Ciarpaglini1, Carlos Fernandez-Sellers1, Noelia Tarazona2, Susana Roselló2, Marisol Huerta2, Desamparados Roda2, Cristina Mongort2, Antonio Ferrández1, Samuel Navarro3, Andres Cervantes2.   

Abstract

AIMS: It is recommended that tumour budding in colon cancer be counted on haematoxylin and eosin-stained sections in a hotspot area of 0.785 mm2 with a ×20 microscope objective. However, tumour buds may be difficult to visualise on haematoxylin and eosin-stained sections, and counting in such a limited area may result in overestimation in cases with focal budding. The aim of this study was to assess the contributions of various factors to improving tumour budding risk stratification: increasing the number of fields counted, using cytokeratin immunostaining, and recording proliferation, the apoptotic index and the emperipoletic index in tumour buds. METHODS AND
RESULTS: We created an exploratory series composed of 172 cases of colon cancer in all stages, and we analysed the survival probability in a second cohort of 158 stage I-II patients. According to our results, counting of budding in 10 fields was the only factor that was significantly correlated with disease-free survival probability in stage I-II patients [hazard ratio (HR) for high versus low grade of 7.64, 95% confidence interval (CI) 5.54-27.92, P = 0.01; HR for intermediate versus low grade of 3.02, 95% CI 1.54-26.72, P = 0.04). Emperipolesis was frequently observed in tumour buds, whereas the mitotic index and the apoptotic index were extremely low. Although cytokeratin immunostaining increased interobserver concordance, it did not improve the accuracy of tumour budding grading.
CONCLUSIONS: According to our results, counting in 10 fields significantly enhanced the budding grade risk stratification in colon cancer patients, and cytokeratin immunostaining could be reserved as a complementary technique for challenging cases with an inflammatory infiltrate and/or striking fibrosis.
© 2019 John Wiley & Sons Ltd.

Entities:  

Keywords:  colon cancer; cytokeratin immunostaining; tumor budding

Mesh:

Year:  2019        PMID: 31081121     DOI: 10.1111/his.13900

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  2 in total

1.  Update of the recommendations for the determination of biomarkers in colorectal carcinoma: National Consensus of the Spanish Society of Medical Oncology and the Spanish Society of Pathology.

Authors:  P García-Alfonso; R García-Carbonero; J García-Foncillas; P Pérez-Segura; R Salazar; R Vera; S Ramón Y Cajal; J Hernández-Losa; S Landolfi; E Musulén; M Cuatrecasas; S Navarro
Journal:  Clin Transl Oncol       Date:  2020-05-16       Impact factor: 3.405

Review 2.  Improving tumor budding reporting in colorectal cancer: a Delphi consensus study.

Authors:  Tariq Sami Haddad; Alessandro Lugli; Susan Aherne; Valeria Barresi; Benoît Terris; John-Melle Bokhorst; Scarlet Fiona Brockmoeller; Miriam Cuatrecasas; Femke Simmer; Hala El-Zimaity; Jean-François Fléjou; David Gibbons; Gieri Cathomas; Richard Kirsch; Tine Plato Kuhlmann; Cord Langner; Maurice B Loughrey; Robert Riddell; Ari Ristimäki; Sanjay Kakar; Kieran Sheahan; Darren Treanor; Jeroen van der Laak; Michael Vieth; Inti Zlobec; Iris D Nagtegaal
Journal:  Virchows Arch       Date:  2021-03-01       Impact factor: 4.064

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.